Is TECX or IMNM more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -32.33% -30.92% Immunome N/A -51.15% -47.32%

Does the media prefer TECX or IMNM?

In the previous week, Immunome had 7 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 10 mentions for Immunome and 3 mentions for Tectonic Therapeutic. Immunome's average media sentiment score of 0.84 beat Tectonic Therapeutic's score of 0.19 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, TECX or KOD?

Kodiak Sciences is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is TECX or KOD more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -32.33% -30.92% Kodiak Sciences N/A -253.85% -81.48%

Does the media prefer TARS or TECX?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for Tarsus Pharmaceuticals and 3 mentions for Tectonic Therapeutic. Tarsus Pharmaceuticals' average media sentiment score of 0.66 beat Tectonic Therapeutic's score of 0.19 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TECX or RGC?

Tectonic Therapeutic presently has a consensus price target of $79.40, indicating a potential upside of 161.44%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 2 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.75 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TECX or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is TECX or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -32.33% -30.92% Regencell Bioscience N/A N/A N/A

Does the media refer more to TECX or RGC?

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Regencell Bioscience's average media sentiment score of 0.55 beat Tectonic Therapeutic's score of 0.19 indicating that Regencell Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, TECX or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is TECX or SLS more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -32.33% -30.92% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media refer more to TECX or SLS?

In the previous week, SELLAS Life Sciences Group had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 9 mentions for SELLAS Life Sciences Group and 3 mentions for Tectonic Therapeutic. SELLAS Life Sciences Group's average media sentiment score of 0.76 beat Tectonic Therapeutic's score of 0.19 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Tectonic Therapeutic (TECX) Competitors

$30.37 -1.24 (-3.92%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$30.36 -0.01 (-0.03%)

As of 07/24/2026 07:34 PM Eastern

Compare

TECX vs. IMNM, KOD, TARS, RGC, and SLS

Should you buy Tectonic Therapeutic stock or one of its competitors? MarketBeat compares Tectonic Therapeutic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tectonic Therapeutic include Immunome (IMNM), Kodiak Sciences (KOD), Tarsus Pharmaceuticals (TARS), Regencell Bioscience (RGC), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

How does Tectonic Therapeutic compare to Immunome?

Tectonic Therapeutic (NASDAQ:TECX) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Tectonic Therapeutic currently has a consensus target price of $79.40, suggesting a potential upside of 161.44%. Immunome has a consensus target price of $33.17, suggesting a potential upside of 49.33%. Given Tectonic Therapeutic's higher possible upside, equities analysts plainly believe Tectonic Therapeutic is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Tectonic Therapeutic has a beta of 3.21, meaning that its stock price is 221% more volatile than the broader market. Comparatively, Immunome has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

Tectonic Therapeutic's return on equity of -32.33% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Immunome	N/A	-51.15%	-47.32%

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tectonic Therapeutic has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Immunome	$4.02M	626.47	-$212.39M	-$2.38	N/A

In the previous week, Immunome had 7 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 10 mentions for Immunome and 3 mentions for Tectonic Therapeutic. Immunome's average media sentiment score of 0.84 beat Tectonic Therapeutic's score of 0.19 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats Immunome on 9 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Kodiak Sciences?

Tectonic Therapeutic (NASDAQ:TECX) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Kodiak Sciences is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Tectonic Therapeutic's return on equity of -32.33% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Kodiak Sciences	N/A	-253.85%	-81.48%

Tectonic Therapeutic presently has a consensus target price of $79.40, indicating a potential upside of 161.44%. Kodiak Sciences has a consensus target price of $42.14, indicating a potential upside of 1.77%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, equities analysts plainly believe Tectonic Therapeutic is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Tectonic Therapeutic had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 1 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.94 beat Tectonic Therapeutic's score of 0.19 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Tectonic Therapeutic	Neutral
Kodiak Sciences	Positive

Tectonic Therapeutic has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market.

Summary

Tectonic Therapeutic beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Tarsus Pharmaceuticals currently has a consensus price target of $90.50, suggesting a potential upside of 54.28%. Tectonic Therapeutic has a consensus price target of $79.40, suggesting a potential upside of 161.44%. Given Tectonic Therapeutic's higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75

Tarsus Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, meaning that its stock price is 221% more volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for Tarsus Pharmaceuticals and 3 mentions for Tectonic Therapeutic. Tarsus Pharmaceuticals' average media sentiment score of 0.66 beat Tectonic Therapeutic's score of 0.19 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals has higher revenue and earnings than Tectonic Therapeutic. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$535.08M	4.72	-$66.42M	-$1.14	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tectonic Therapeutic has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Summary

Tarsus Pharmaceuticals beats Tectonic Therapeutic on 9 of the 14 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Regencell Bioscience?

Tectonic Therapeutic (NASDAQ:TECX) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Tectonic Therapeutic presently has a consensus price target of $79.40, indicating a potential upside of 161.44%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Regencell Bioscience's average media sentiment score of 0.55 beat Tectonic Therapeutic's score of 0.19 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Regencell Bioscience	N/A	N/A	N/A

Tectonic Therapeutic has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market.

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Tectonic Therapeutic beats Regencell Bioscience on 7 of the 11 factors compared between the two stocks.

How does Tectonic Therapeutic compare to SELLAS Life Sciences Group?

Tectonic Therapeutic (NASDAQ:TECX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Tectonic Therapeutic has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market.

Tectonic Therapeutic currently has a consensus target price of $79.40, indicating a potential upside of 161.44%. SELLAS Life Sciences Group has a consensus target price of $10.00, indicating a potential downside of 11.66%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, research analysts clearly believe Tectonic Therapeutic is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Tectonic Therapeutic's return on equity of -32.33% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

In the previous week, SELLAS Life Sciences Group had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 9 mentions for SELLAS Life Sciences Group and 3 mentions for Tectonic Therapeutic. SELLAS Life Sciences Group's average media sentiment score of 0.76 beat Tectonic Therapeutic's score of 0.19 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	3 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats SELLAS Life Sciences Group on 10 of the 14 factors compared between the two stocks.

Get Tectonic Therapeutic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECX vs. The Competition

Export

Metric	Tectonic Therapeutic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$573.05M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-6.81	21.11	27.00	23.71
Price / Sales	N/A	163.85	492.30	74.42
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	2.26	7.88	10.28	6.07
Net Income	-$74.15M	$23.81M	$3.60B	$331.99M
7 Day Performance	-6.84%	-3.82%	-1.29%	-0.61%
1 Month Performance	-2.13%	-2.61%	-0.38%	-1.98%
1 Year Performance	36.07%	32.79%	18.32%	13.67%

Tectonic Therapeutic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECX Tectonic Therapeutic	3.2994 of 5 stars	$30.37 -3.9%	$79.40 +161.4%	+36.3%	$573.05M	N/A	N/A	120
IMNM Immunome	3.2486 of 5 stars	$22.59 -0.9%	$33.17 +46.8%	+97.6%	$2.58B	$6.94M	N/A	40	News Coverage Analyst Forecast
KOD Kodiak Sciences	1.083 of 5 stars	$43.26 +5.3%	$42.14 -2.6%	+401.9%	$2.57B	N/A	N/A	90	Gap Up
TARS Tarsus Pharmaceuticals	3.287 of 5 stars	$56.11 -5.4%	$90.67 +61.6%	+38.2%	$2.55B	$451.36M	N/A	50	Analyst Forecast
RGC Regencell Bioscience	0.2632 of 5 stars	$5.65 +11.9%	N/A	-62.3%	$2.50B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tectonic Therapeutic (TECX) Competitors

TECX vs. IMNM, KOD, TARS, RGC, and SLS

How does Tectonic Therapeutic compare to Immunome?

Summary

How does Tectonic Therapeutic compare to Kodiak Sciences?

Summary

How does Tectonic Therapeutic compare to Tarsus Pharmaceuticals?

Summary

How does Tectonic Therapeutic compare to Regencell Bioscience?

Summary

How does Tectonic Therapeutic compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tectonic Therapeutic (TECX) Competitors

TECX vs. IMNM, KOD, TARS, RGC, and SLS

How does Tectonic Therapeutic compare to Immunome?

Do analysts rate TECX or IMNM?

Which has more risk & volatility, TECX or IMNM?

Is TECX or IMNM more profitable?

Do institutionals & insiders hold more shares of TECX or IMNM?

Which has higher earnings & valuation, TECX or IMNM?

Does the media prefer TECX or IMNM?

Summary

How does Tectonic Therapeutic compare to Kodiak Sciences?

Which has better valuation & earnings, TECX or KOD?

Is TECX or KOD more profitable?

Do analysts prefer TECX or KOD?

Do institutionals and insiders believe in TECX or KOD?

Does the media prefer TECX or KOD?

Which has more risk and volatility, TECX or KOD?

Summary

How does Tectonic Therapeutic compare to Tarsus Pharmaceuticals?

Do analysts recommend TARS or TECX?

Which has more risk and volatility, TARS or TECX?

Does the media prefer TARS or TECX?

Which has better earnings & valuation, TARS or TECX?

Do insiders and institutionals have more ownership in TARS or TECX?

Is TARS or TECX more profitable?

Summary

How does Tectonic Therapeutic compare to Regencell Bioscience?

Do analysts prefer TECX or RGC?

Which has better earnings and valuation, TECX or RGC?

Does the media refer more to TECX or RGC?

Is TECX or RGC more profitable?

Which has more risk & volatility, TECX or RGC?

Do insiders and institutionals believe in TECX or RGC?

Summary

How does Tectonic Therapeutic compare to SELLAS Life Sciences Group?

Which has more volatility & risk, TECX or SLS?

Do analysts rate TECX or SLS?

Is TECX or SLS more profitable?

Do insiders & institutionals hold more shares of TECX or SLS?

Which has higher earnings & valuation, TECX or SLS?

Does the media refer more to TECX or SLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools